{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:34:45Z","timestamp":1767850485069,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ejpb.2022.07.006","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T12:06:44Z","timestamp":1658146004000},"page":"260-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Crizotinib prodrug micelles co-delivered doxorubicin for synergistic immunogenic cell death induction on breast cancer chemo-immunotherapy"],"prefix":"10.1016","volume":"177","author":[{"given":"Qiangwei","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2022.07.006_b0005","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.actbio.2017.11.010","article-title":"Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy","volume":"66","author":"Liu","year":"2018","journal-title":"Acta Biomater."},{"issue":"30","key":"10.1016\/j.ejpb.2022.07.006_b0010","doi-asserted-by":"crossref","first-page":"14554","DOI":"10.1039\/C8NR03611J","article-title":"Photodynamic therapy-mediated remote control of chemotherapy toward synergistic anticancer treatment","volume":"10","author":"Li","year":"2018","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejpb.2022.07.006_b0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.canlet.2020.08.041","article-title":"Co-administration of sulforaphane and doxorubicin attenuates breast cancer growth by preventing the accumulation of myeloid-derived suppressor cells","volume":"493","author":"Rong","year":"2020","journal-title":"Cancer Lett."},{"issue":"37","key":"10.1016\/j.ejpb.2022.07.006_b0020","doi-asserted-by":"crossref","first-page":"e2101897","DOI":"10.1002\/smll.202101897","article-title":"Reinforcing the Induction of Immunogenic Cell Death Via Artificial Engineered Cascade Bioreactor-Enhanced Chemo-Immunotherapy for Optimizing Cancer Immunotherapy","volume":"17","author":"Sun","year":"2021","journal-title":"Small"},{"key":"10.1016\/j.ejpb.2022.07.006_b0025","doi-asserted-by":"crossref","first-page":"697964","DOI":"10.3389\/fimmu.2021.697964","article-title":"Immunogenic Cell Death-Based Cancer Vaccines","volume":"12","author":"Jin","year":"2021","journal-title":"Front. Immunol."},{"issue":"41","key":"10.1016\/j.ejpb.2022.07.006_b0030","doi-asserted-by":"crossref","first-page":"45873","DOI":"10.1021\/acsami.0c14405","article-title":"Tumor Microenvironment-Triggered Charge Reversal Polymetformin-Based Nanosystem Co-Delivered Doxorubicin and IL-12 Cytokine Gene for Chemo-Gene Combination Therapy on Metastatic Breast Cancer","volume":"12","author":"Sun","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.ejpb.2022.07.006_b0035","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12951-021-01011-2","article-title":"Regulating immune memory and reversing tumor thermotolerance through a step-by-step starving-photothermal therapy","volume":"19","author":"Luo","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejpb.2022.07.006_b0040","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jconrel.2021.07.021","article-title":"Cancer-cell-biomimetic Upconversion nanoparticles combining chemo-photodynamic therapy and CD73 blockade for metastatic triple-negative breast cancer","volume":"337","author":"Jin","year":"2021","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.ejpb.2022.07.006_b0045","doi-asserted-by":"crossref","first-page":"11041","DOI":"10.1021\/acsnano.8b05189","article-title":"Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway","volume":"12","author":"Lu","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2022.07.006_b0050","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.actbio.2019.03.048","article-title":"Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy","volume":"90","author":"Wan","year":"2019","journal-title":"Acta Biomater."},{"issue":"4","key":"10.1016\/j.ejpb.2022.07.006_b0055","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/acsnano.0c00708","article-title":"Icaritin Exacerbates Mitophagy and Synergizes with Doxorubicin to Induce Immunogenic Cell Death in Hepatocellular Carcinoma","volume":"14","author":"Yu","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2022.07.006_b0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.ejpb.2022.07.006_b0065","doi-asserted-by":"crossref","first-page":"1596652","DOI":"10.1080\/2162402X.2019.1596652","article-title":"Crizotinib - a tyrosine kinase inhibitor that stimulates immunogenic cell death","volume":"8","author":"Liu","year":"2019","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ejpb.2022.07.006_b0070","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/s41467-019-09415-3","article-title":"Crizotinib-induced immunogenic cell death in non-small cell lung cancer","volume":"10","author":"Liu","year":"2019","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ejpb.2022.07.006_b0075","doi-asserted-by":"crossref","first-page":"337","DOI":"10.21037\/jgo.2020.01.06","article-title":"Relationship between IL-10 and PD-L1 in esophageal carcinoma tissues and IL-10 down-regulates PD-L1 expression via Met signaling pathway","volume":"11","author":"Qian","year":"2020","journal-title":"J. Gastrointest. Oncol."},{"issue":"1","key":"10.1016\/j.ejpb.2022.07.006_b0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10637-020-00989-0","article-title":"Crizotinib induced antitumor activity and synergized with chemotherapy and hormonal drugs in breast cancer cells via downregulating MET and estrogen receptor levels","volume":"39","author":"Ayoub","year":"2021","journal-title":"Invest. New Drugs"},{"issue":"2","key":"10.1016\/j.ejpb.2022.07.006_b0085","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1166\/jbn.2018.2481","article-title":"Silver-Coated Nanoparticles Combined with Doxorubicin for Enhanced Anticancer Therapy","volume":"14","author":"Yang","year":"2018","journal-title":"J. Biomed. Nanotechnol."},{"issue":"8","key":"10.1016\/j.ejpb.2022.07.006_b0090","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1021\/acs.molpharmaceut.6b00708","article-title":"Unimolecular Micelles of Amphiphilic Cyclodextrin-Core Star-Like Copolymers with Covalent pH-Responsive Linkage of Anticancer Prodrugs","volume":"14","author":"Jia","year":"2017","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.ejpb.2022.07.006_b0095","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jnci\/djy131","article-title":"Combining Tumor Microenvironment Modulating Nanoparticles with Doxorubicin to Enhance Chemotherapeutic Efficacy and Boost Antitumor Immunity","volume":"111","author":"Amini","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"issue":"116781","key":"10.1016\/j.ejpb.2022.07.006_b0100","article-title":"Chitosan based pH-responsive polymeric prodrug vector for enhanced tumor targeted co-delivery of doxorubicin and siRNA","volume":"250","author":"Yan","year":"2020","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2022.07.006_b0105","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.actbio.2020.11.008","article-title":"Tumor microenvironment-activated therapeutic peptide-conjugated prodrug nanoparticles for enhanced tumor penetration and local T cell activation in the tumor microenvironment","volume":"119","author":"Zhu","year":"2021","journal-title":"Acta Biomater."},{"issue":"3","key":"10.1016\/j.ejpb.2022.07.006_b0110","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.7150\/thno.38287","article-title":"High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy","volume":"10","author":"Sun","year":"2020","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.ejpb.2022.07.006_b0115","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.7150\/thno.38973","article-title":"Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier","volume":"10","author":"Ma","year":"2020","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.ejpb.2022.07.006_b0120","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1021\/acs.molpharmaceut.9b00209","article-title":"Co-Delivery of Paclitaxel by a Capsaicin Prodrug Micelle Facilitating for Combination Therapy on Breast Cancer","volume":"16","author":"Lan","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2022.07.006_b0125","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jpba.2018.03.053","article-title":"Simple and sensitive LC-MS\/MS method for simultaneous determination of crizotinib and its major oxidative metabolite in human plasma: Application to a clinical pharmacokinetic study","volume":"155","author":"Qi","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"20","key":"10.1016\/j.ejpb.2022.07.006_b0130","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1039\/D0BM01191F","article-title":"Dual polymeric prodrug co-assembled nanoparticles with precise ratiometric co-delivery of cisplatin and metformin for lung cancer chemoimmunotherapy","volume":"8","author":"Yang","year":"2020","journal-title":"Biomater. Sci."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641122001448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641122001448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:49:58Z","timestamp":1760546998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641122001448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":26,"alternative-id":["S0939641122001448"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.07.006","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crizotinib prodrug micelles co-delivered doxorubicin for synergistic immunogenic cell death induction on breast cancer chemo-immunotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}